Phathom Pharmaceuticals, Inc. Common Stock
PHATPhathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company aims to address unmet medical needs through innovative therapies, with a particular emphasis on conditions such as acid-related disorders.
Company News
Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.
The article discusses the top 3 most-shorted stocks in August, including Beyond Meat (BYND), Phathom Pharmaceuticals (PHAT), and Groupon (GRPN). It analyzes the short interest, financial performance, and market outlook for each company.
Stay up to date with the latest financial news! Listen to the Wall Street Breakfast podcast on Seeking Alpha, iTunes, and Spotify.
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 0.70% and 30.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. Shares of Walmart Inc. (NYSE: WMT) rose in today’s session after the company reported better-than-expected fourth-quarter financial results. Walmart reported fourth-quarter FY24 net sales growth of 5.7% year-over-year to $173.39 billion, beating t...
